Head & Neck Cancers

Xevinapant Combination Induced Significant Overall Survival Improvements in LA-SCCHN

September 19, 2020

The addition og xevinapant to standard cisplatin-based concomitant fractionation chemoradiation therapy led to a reduction in the risk of mortality as treatment of patients with locally advanced squamous cell carcinoma of the head and neck.

Novel IAP Inhibitor Shows Significant OS Benefit for High-Risk Head and Neck Cancer

August 13, 2020

Debio 1143, a potential first-in-class inhibitor of apoptosis proteins, demonstrated a statistically and clinically significant overall survival improvement when used in combination with chemoradiotherapy as treatment of patients with high-risk locally advanced squamous cell carcinoma of the head and neck, according to a press release from Debiopharm.

Avelumab Plus TG4001 Shows Promising Efficacy in HPV16-Positive Metastatic Cancers

July 23, 2020

Avelumab in combination with a novel HPV16-targeted vaccine, demonstrated clinical activity as treatment of patients with HPV16-positive recurrent and/or metastatic malignancies.

Dysphagia-Optimized IMRT Shows Significance in Head and Neck Cancer

July 15, 2020

Christopher Nutting, MD, discusses the results of a randomized phase 3 trial using dysphagia-optimized intensity modulated radiotherapy versus standard IMRT in patients with head and neck cancer.

FDA Expanded Approval for Preventative Vaccine of HPV-Associated Oropharyngeal and Other Head and Neck Cancers

June 15, 2020

“Today’s approval for the prevention of HPV-related oropharyngeal and other head and neck cancers represents an important step in Merck’s mission to help reduce the number of men and women affected by certain HPV-related cancers.”

Pembrolizumab Increases 24-Month PFS2 in PD-L1+ HNSCC

May 30, 2020

Overall, these data support the use of pembrolizumab and pembrolizumab plus chemotherapy as first-line treatment of patients with relapsed and/or metastatic HNSCC.

Rationale for Evaluating STING Agonists in Head and Neck Cancer

April 27, 2020

Robert L. Ferris, MD, PhD, discusses the rationale for evaluating STING agonists as treatment for patients with head and neck cancers.

FDA Grants Pembrolizumab Priority Review for TMB-High Tumors

April 07, 2020

The FDA has accepted and granted a priority review to a supplemental Biologics License Application for pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors with tissue tumor mutational burden-high who have progressed following prior treatment and who have no satisfactory alternative treatment options.

Chemotherapy Toxicity Correlates With Nutritional Factors in Solid Tumors

March 30, 2020

An association was found between a lower risk of grade 3 or higher chemotherapy toxicity with higher body mass indexes and normal albumin, a protein made in the liver, levels in older adult patients with solid tumors, according to an analysis of a prospective, multicenter study.

COVID-19 Presents an Opportunity for Precision Medicine to Play Expanded Role in Care

March 30, 2020

A sudden surge in the cases of COVID-19 due to pandemic, along with efforts to contain it, has led to multiple challenges that no country has experienced in the last several decades. The global pandemic from COVID-19 poses a unique set of challenges not only for patients with cancer who need their treatment, but also for caregivers, oncologists, and the overall care team.